Recorded Presentation from the NCCN Pharmacy Updates: Advances in Targeted Therapy and Immunotherapy for the Treatment of Kidney Cancer
Pharmacists should be aware of data on targeted therapy and immunotherapy for RCC and be able to make appropriate therapy recommendations. In addition, pharmacists play an important role in the management of toxicity of targeted therapy or immunotherapy and encouraging compliance for patients on targeted therapies for RCC.
Category
  • Kidney Cancer
Format
  • Recorded Webcast
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation
Recorded Presentation from the NCCN Pharmacy Updates: Current Therapy Options for Graft-Versus-Host Disease
Both acute and chronic graft-versus-host disease, while fairly common in allogeneic HSCT, can be potentially fatal. The clinical manifestations of this complication can linger for years and often times impair quality of life drastically. Hematology and oncology specialists can optimize care by early recognition and prompt initiation of systemic therapies.
Category
  • Supportive Care Topics
Format
  • Recorded Webcast
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation
Recorded Presentation from the NCCN Pharmacy Updates: New Targets and Treatment Options for Acute Myeloid Leukemia
Recent advances have led to rational drug development as new therapeutically actionable molecular targets have emerged. It is important for clinicians to be aware of how to incorporate these novel treatment options into clinical practice in ways that achieve meaningful patient outcomes, as well as best practices for providing supportive care and patient education.
Category
  • Acute Myelogenous Leukemia
Format
  • Recorded Webcast
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation
Recorded Presentation from the NCCN Pharmacy Updates: Updates on the Use of Immunotherapy and Targeted Therapy in Non-Small Cell Lung Cancer
Many new options exist for the treatment of advanced non-small cell lung cancer (NSCLC) in addition to traditional platinum-based chemotherapy. Pharmacists should be aware of the new data and recommendations for immunotherapies and targeted therapies, and how they relate to improvements in clinical efficacy and quality of life. It is also important to be aware of the potential for unique and potentially severe adverse events that can occur with these therapies; therefore, pharmacists should educate patients about the possibility of adverse events and the need to report symptoms to their health care teams to avoid severe complications.
Category
  • Lung Cancers
Format
  • Recorded Webcast
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation
Recorded Presentation from the NCCN Pharmacy Updates: The Role of the Pharmacist in Smoking Cessation and Education of Patients with Cancer
In order to improve smoking cessation efforts, health care providers need to understand options for smoking cessation therapy as well as the clinical data supporting these interventions. Pharmacists can play a critical role in patient education, therapy recommendations, and therapy management for smoking cessation.
Category
  • Supportive Care Topics
Format
  • Recorded Webcast
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation
Current Topics in Management of Non-Muscle Invasive Bladder Cancer
Non–muscle invasive bladder cancer (NMIBC) is the most commonly diagnosed form of bladder cancer. Better understanding of recommended treatment strategies during a bacillus Calmette Guérin (BCG) shortage, as well as familiarity with novel treatment options that may be on the horizon, will help educate clinicians on how to optimally treat NMIBC.
Category
  • Bladder Cancer
Format
  • Recorded Webcast
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation
Selection of Optimal First-Line and Maintenance Therapies in Advanced Ovarian Cancer
Because randomized trial data has shown that many of the options for primary chemotherapy in patients with advanced ovarian cancer have similar outcomes, the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Ovarian Cancer includes a large list of regimens – including in
Category
  • Ovarian Cancer
Format
  • Recorded Webcast
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation
Optimizing the Management of Endometrial Cancer
The introduction of new methods for classifying endometrial cancers and assessing risk can create a challenging landscape for clinicians to navigate when evaluating patients and determining appropriate treatment. Education is needed to help clinicians apply updates to the NCCN Guidelines in their practice in order to promote optimal care of patients with endometrial cancer.
Category
  • Endometrial Cancer
Format
  • Recorded Webcast
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation
Recorded Presentation from the NCCN Pharmacy Updates: New Targets in Breast Cancer Therapy
Triple-negative breast cancer continues to be labeled with a poor prognosis secondary to the fact that it tends to be more aggressive and poses a greater risk of recurrence. Because it lacks the receptors that many drugs have been designed to target, the standard of practices remains chemotherapy. Therefore, research has been focused on trying to identify other therapeutic targets for which we already have agents or are currently developing agents.
Category
  • Breast Cancer
Format
  • Recorded Webcast
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation
Archived Monthly Oncology Tumor Boards: A Multidisciplinary Approach to Individualized Patient Care - Breast Cancer
Staying up-to-date with the available treatment options is important for health care professionals to integrate new evidence-based data into their clinical practice, and being familiar with the toxicity profile is important to optimize patient outcomes.
Category
  • Breast Cancer
Format
  • Recorded Webcast
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • CCM clock hours
  • Participation

Pages